COLL News and Press, Collegium Pharmaceutical Inc. From 05/13/24

2024-05-13 15:23:02 ET Summary Collegium Pharmaceutical, Inc. stock fell 16% on Friday after Q1 results missed expectations and a CEO replacement was announced. Despite the negative reaction, there were some positive aspects in the results and guidance. An updated analysis aro...

2024-05-13 09:06:09 ET More on Collegium Pharmaceutical Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript Collegium Pharmaceutical Q4: The Beat Goes On Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript Collegium downgrade...

STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated ...

2024-05-10 13:12:30 ET More on Collegium Pharmaceutical Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript Collegium Pharmaceutical Q4: The Beat Goes On Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript Collegium announces...

2024-05-10 01:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-09 19:32:08 ET Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Results Conference Call May 09, 2024 04:30 PM ET Company Participants Christopher James - Vice President of Investor Relations Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Finan...

2024-05-09 16:29:16 ET More on Collegium Pharmaceutical Collegium Pharmaceutical Q4: The Beat Goes On Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript Collegium Pharmaceutical, Inc. 2023 Q4 - Results - Earnings Call Presentation Collegium Ph...

2024-05-09 16:16:01 ET More on Collegium Pharmaceutical Collegium Pharmaceutical Q4: The Beat Goes On Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript Collegium Pharmaceutical, Inc. 2023 Q4 - Results - Earnings Call Presentation Collegium Ph...

– Generated Q1’24 Net Revenue of $144.9 Million – – Delivered Q1’24 Record Belbuca ® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1’24 GAAP Net Income of $27.7 Million ...

– Joe Ciaffoni to Step Down as President and Chief Executive Officer – – Board Chairman Michael Heffernan to Serve as Interim President and Chief Executive Officer – – Board of Directors has Initiated the Search for a Successor – S...